11 research outputs found
Stereotactic radiosurgery for the treatment of recurrent high-grade gliomas: long-term follow-up
High-grade gliomas (HGG) are the most frequent primary central nervous system tumors; treatment of HCGs
includes surgery and post-operative conformal radiotherapy associated with temozolomide (TMZ or
procarbazine/lomustine/vincristine [PCV], specifically in patients with anaplastic oligodendrogliomas or
anaplastic oligoastrocytomas). However, recurrence is common. Re-irradiation has been utilized in this
setting for years and remains a feasible option, although there is always a concern regarding toxicity.
Modern high-precision conformal techniques, including stereotactic radiosurgery (SRS), could improve the
therapeutic ratio by delivering high biologically equivalent doses while reducing high-dose radiotherapy (RT)
to normal brain tissue. In this paper, we present the results obtained after prolonged follow-up in patients
who underwent SRS as a treatment for recurrent high-grade gliomas at San Francisco Hospital in Madrid,
Spain
Does endovascular treatment with curative intention have benefits for treating High-grade AVM versus radiosurgery? Efficacy, safety, and cost-effectiveness analysis
BACKGROUND: The treatment of high-grade arteriovenous malformations (AVMs) remains challenging. Microsurgery provides a rapid and complete occlusion compared to other options, but is associated with undesirable morbidity and mortality. The aim of this study was to compare the occlusion rates, incidence of unfavorable outcomes, and cost-effectiveness of embolization and stereotactic radiosurgery (SRS) as a curative treatment for high-grade AVMs.METHODS: A retrospective series of 57 consecutive patients with high-grade AVM treated with embolization or SRS, with the aim of achieving complete occlusion, was analyzed. Demographic, clinical, and angio-architectonic variables were collected. Both treatments were compared for the occlusion rate and procedure-related complications. In addition, a cost-effectiveness analysis was performed.RESULTS: Thirty (52.6%) patients were men and 27 (47.4%) were women (mean age 39 years). AVMs were unruptured in 43 (75.4%) patients, and ruptured in 14 (24.6%) patients. The presence of deep venous drainage, nidus volume, perforated arterial supply, and eloquent localization were more frequent in the SRS group. Complications such as hemorrhage or worsening of previous seizures were more frequent in the embolization group. No significant differences were observed in the occlusion rates or in the time necessary to achieve occlusion between the groups. The incremental cost-effectiveness ratio for endovascular treatment vs. SRS was $ 53.279.CONCLUSION: Both techniques achieved similar occlusion rates, but SRS carried a lower risk of complications. Staged embolization may be associated with a greater risk of hemorrhage, while SRS was demonstrated to have a better cost-effectiveness ratio. These results support SRS as a better treatment option for high-grade AVMs
Role of the radiosurgery in the treatment of cerebral arterio- venous malformations : review of the literature and analysis of results.
Stereotactic radiosurgery for the treatment of recurrent high-grade gliomas: long-term follow-up
High-grade gliomas (HGG) are the most frequent primary central nervous system tumors; treatment of HCGs
includes surgery and post-operative conformal radiotherapy associated with temozolomide (TMZ or
procarbazine/lomustine/vincristine [PCV], specifically in patients with anaplastic oligodendrogliomas or
anaplastic oligoastrocytomas). However, recurrence is common. Re-irradiation has been utilized in this
setting for years and remains a feasible option, although there is always a concern regarding toxicity.
Modern high-precision conformal techniques, including stereotactic radiosurgery (SRS), could improve the
therapeutic ratio by delivering high biologically equivalent doses while reducing high-dose radiotherapy (RT)
to normal brain tissue. In this paper, we present the results obtained after prolonged follow-up in patients
who underwent SRS as a treatment for recurrent high-grade gliomas at San Francisco Hospital in Madrid,
Spain
EANO guideline on the diagnosis and treatment of vestibular schwannoma
The level of evidence to provide treatment recommendations for vestibular schwannoma is low compared with other intracranial neoplasms. Therefore, the vestibular schwannoma task force of the European Association of Neuro-Oncology assessed the data available in the literature and composed a set of recommendations for health care professionals.The radiological diagnosis of vestibular schwannoma is made by magnetic resonance imaging. Histological verification of the diagnosis is not always required. Current treatment options include observation, surgical resection, fractionated radiotherapy, and radiosurgery. The choice of treatment depends on clinical presentation, tumor size, and expertise of the treating center. In small tumors, observation has to be weighed against radiosurgery, in large tumors surgical decompression is mandatory, potentially followed byfractionated radiotherapy or radiosurgery. Except for bevacizumab in neurofibromatosis type 2, there is no role for pharmacotherapy
EANO guidelines for the diagnosis and treatment of meningiomas
Although meningiomas are the most common intracranial tumours, the level of evidence to provide recommendations for the diagnosis and treatment of meningiomas is low compared with other tumours such as high-grade gliomas. The meningioma task force of the European Association of Neuro-Oncology (EANO) assessed the scientific literature and composed a framework of the best possible evidence-based recommendations for health professionals. The provisional diagnosis of meningioma is mainly made by MRI. Definitive diagnosis, including histological classification, grading, and molecular profiling, requires a surgical procedure to obtain tumour tissue. Therefore, in many elderly patients, observation is the best therapeutic option. If therapy is deemed necessary, the standard treatment is gross total surgical resection including the involved dura. As an alternative, radiosurgery can be done for small tumours, or fractionated radiotherapy in large or previously treated tumours. Treatment concepts combining surgery and radiosurgery or fractionated radiotherapy, which enable treatment of the complete tumour volume with low morbidity, are being developed. Pharmacotherapy for meningiomas has remained largely experimental. However, antiangiogenic drugs, peptide receptor radionuclide therapy, and targeted agents are promising candidates for future pharmacological approaches to treat refractory meningiomas across all WHO grades
EANO guideline on the diagnosis and management of meningiomas
Meningiomas are the most common intracranial tumors. Yet, only few controlled clinical trials have been conducted to guide clinical decision making, resulting in variations of management approaches across countries and centers. However, recent advances in molecular genetics and clinical trial results help to refine the diagnostic and therapeutic approach to meningioma. Accordingly, the European Association of Neuro-Oncology (EANO) updated its recommendations for the diagnosis and treatment of meningiomas. A provisional diagnosis of meningioma is typically made by neuroimaging, mostly magnetic resonance imaging. Such provisional diagnoses may be made incidentally. Accordingly, a significant proportion of meningiomas, notably in patients that are asymptomatic or elderly or both, may be managed by a watch-and-scan strategy. A surgical intervention with tissue, commonly with the goal of gross total resection, is required for the definitive diagnosis according to the WHO classification. A role for molecular profiling including gene panel sequencing and genomic methylation profiling is emerging. A gross total surgical resection including the involved dura is often curative. Inoperable or recurrent tumors requiring treatment can be treated with radiosurgery, if the size or the vicinity of critical structures allows that, or with fractionated radiotherapy (RT). Treatment concepts combining surgery and radiosurgery or fractionated RT are increasingly used, although there remain controversies regard timing, type, and dosing of the various RT approaches. Radionuclide therapy targeting somatostatin receptors is an experimental approach, as are all approaches of systemic pharmacotherapy. The best albeit modest results with pharmacotherapy have been obtained with bevacizumab or multikinase inhibitors targeting vascular endothelial growth factor receptor, but no standard of care systemic treatment has been yet defined